Paloma Partners’s Ascendis Pharma A/S ASND Stock Holding History

Paloma Partners’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-2,099	Closed	-$276K	–	1071
2021 Q2	$276K	Buy	+2,099	New	+$280K	0.01%	1357
2020 Q1	–	Sell	-1,594	Closed	-$222K	–	1241
2019 Q4	$222K	Buy	+1,594	New	+$177K	﹤0.01%	1925

Other funds holding ASND

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Paloma Partners's ASND Position: Q3 2021 in Review

Paloma Partners sold out of Ascendis Pharma A/S (ASND) in Q3 2021, closing a stake of 2,099 shares — an estimated $276K sold.

Paloma Partners first reported a position in ASND in Q4 2019 and held it in 2 quarters. The position peaked at $276K in Q2 2021. 166 funds tracked by Wall St. Rank hold ASND as of Q3 2021.

Paloma Partners reported no remaining Ascendis Pharma A/S position as of Q3 2021 after selling out during the quarter.
Paloma Partners sold 2,099 Ascendis Pharma A/S shares in Q3 2021, an estimated $276K.
Paloma Partners first reported a position in Ascendis Pharma A/S in Q4 2019 and held it in 2 quarters.
Paloma Partners's Ascendis Pharma A/S position peaked at $276K in Q2 2021.
166 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q3 2021.

Based on Paloma Partners's 13F filing for Q3 2021, filed 15 Nov 2021.